Weekly monitoring identified week 2 triggers for nodal targets and contralateral parotids, with later week 4 triggers for primary targets.
K-means matched hybrid optimization for margin volume while reducing median computation time from 306.9 seconds to 0.19 seconds.
98.98% of virtual contrast-enhanced MRI scans were rated suitable for diagnosis, and 92.33% for tumor delineation.
A physics-constrained network reconstructed pelvic cone-beam computed tomography from two simulated radiographs with substantially lower error than generative baselines.
Respiratory gating more than halved cranio-caudal motion, while motion-related target-dose deviations largely diminished after accumulation across more than three fractions.
No single patient-specific quality assurance method covered all stereotactic radiotherapy risks, supporting combinations of measurement, independent calculation, imaging, and monitoring.
Mean treated-breast displacement was 1.6 mm, with larger patient-specific changes near treatment completion and during follow-up.
A 3D-printed jig delivered approximately uniform iridium-192 tumor dose, delayed tumor growth, and caused no observable short-term radiation toxicity in mice.
Hybrid phase-amplitude gating restored dose agreement during regular motion, while irregular breathing increased treatment time and produced inconsistent accuracy.
Off-axis beam optimization preserved target coverage while reducing lung dose and enabling collision-free beam geometry for posterior lung lesions.
Robust optimization preserved target coverage while reducing lung, heart, esophageal, spinal cord, and estimated immune-cell dose during long-course lung radiotherapy.
Multimodal registration, motion management, and arrhythmia substrate definition were the highest-risk steps in stereotactic arrhythmia radioablation.
The neural model reduced phase-space storage from 3 gigabytes to 600 kilobytes while maintaining at least 89.9% gamma passing at 1%/1 mm.
The framework achieved 85.5% external-validation accuracy and reduced estimated review time from 822 hours to 2.3–4.8 hours.
Absorbed dose near the applicator varied markedly by tissue composition despite accurate Monte Carlo calculation by the treatment planning system.